Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial
John A. Glaspy(University of California, Los Angeles), Greg Rossi(Amgen (United States)), Linda D. Bosserman(City of Hope), Richard E. Lloyd(Baylor College of Medicine), Eddie Hu(Amgen (United States)), Dianne Tomita, Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Ravi Patel(Comprehensive Blood & Cancer Center)
Cited by 78
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425